LIPO-V inhibits Radiation Induced Gastrointestinal Syndrome (RIGS)
Novel pharmaceutical composition (LIPO-V) is a modulator of WNT signaling induces for repair and regeneration of intestinal epithelium. LIPO-V protects/mitigates RIGS following acute gastrointestinal (GI) radiation exposure.
Project Team
Institutions
Project Status
Funding Opportunity
Background
Although a few drugs are available which can protect radiation injury if applied prior to radiation exposure, to date there are no agents available, which can be applied 24 hour post-exposure to mitigate the acute radiation syndrome. The high radiosensitivity of the intestinal epithelium increases susceptibility to RIGS, and with mortality within 10-15 days there is limited time for therapeutic intervention. KU inventors have shown that mice receiving LIPO-V at 24 hours after lethal dose of whole body irradiation mitigates radiation injury in intestine and improves survival in these mice. Histopathological analysis clearly demonstrated the repair and regeneration of intestinal epithelium in response to LIPO-V treatment.
Project Details
Novel pharmaceutical composition (LIPO-V) is a modulator of WNT signaling induces for repair and regeneration of intestinal epithelium. LIPO-V protects/mitigates RIGS following acute gastrointestinal (GI) radiation exposure. The first non-prophylactic therapy to mitigate RIGS that can be used within 24 hours of acute radiation exposure. LIPO-V could in theory be used to protect against radiation-induced injury to other sensitive tissues besides the GI, such as lung, liver and heart. Due to the broad effects of WNT signaling, LIPO-V could be used to protect against chemotherapy-induced toxicities as well.